NASDAQ$ACLX
Arcellx Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Arcellx reported Q2 2025 a net loss of $52.8M, diluted EPS of $-0.94.
For Q2 2025, Arcellx reported net loss was $52.8M, diluted EPS was $-0.94. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $52.8M.
- Diluted EPS $-0.94.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$7.55M
Forward guidance
Biopharma outlook emphasizes pipeline milestones, launch uptake, and R&D spend.
Tailwinds
- Clinical data and partnership economics.
- Cash runway supports key readouts.
Headwinds
- Trial risk and regulatory timelines.
- Competition and reimbursement pressure.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro